A recent study carried out by a laboratory at the Pasteur Institute of Tunisia, on the cost and effects of vaccination against human papillomavirus (HPV), revealed the importance of this vaccination as an effective measure to reduce the incidence of cervical cancer.
The same study indicates that HPV vaccination reduces the high costs of treating advanced cervical cancer.
The papillomavirus causes a number of cancers, including cervical cancer, but it can be prevented by vaccination and early detection, according to the study.
The results of this study were presented last week during a scientific day at the Pasteur Institute in Tunis, in the presence of around 80 participants, including representatives of the Ministry of Health, health experts, economists from health, members of scientific associations and representatives of UNICEF.
It is important to mention that cervical cancer is the fourth most common cancer among women in Tunisia in 2023, according to official statistics from the epidemiology department of the Salah Azaïz Institute. In 2025, the Ministry of Health plans to include vaccination against cervical cancer for the first time in the national vaccination schedule for girls aged 12 to 14 years.
